on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Receives Approval for GalliaPharm® in Japan
Berlin, 19 September 2025 – Eckert & Ziegler Radiopharma GmbH, a leading provider in isotope technology for nuclear medicine, has gained approval from Japan's Ministry of Health for its GalliaPharm® 68Ge/68Ga Radionuclide Generator. This development, facilitated through Novartis Pharma K.K., marks a significant advancement in the availability of Gallium-68 diagnostics in Japan, particularly for PET imaging related to prostate cancer.
The approval allows the usage of the Novartis kit Locametz® for the preparation of 68Ga-PSMA-11. GalliaPharm®, an established GMP-grade generator, is internationally recognized and supports accurate imaging crucial for early diagnosis. Dr. Deljana Werner emphasized the importance of this clearance for enhanced imaging capabilities in Japanese healthcare.
This move signals Eckert & Ziegler's commitment to broadening access to reliable isotope technologies and fostering global innovation in molecular imaging.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news